Mod GRF 1-29 Lab Monitoring: Blood Work Guide | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Mod GRF 1-29 lab monitoring

Lab guideLast updated: October 28, 2026

Which blood work to run before, during and after a Mod GRF 1-29 (CJC-1295 without DAC) cycle, and what the research can and can't tell you about the results. There are no published human studies of Mod GRF 1-29 at all (PMID 42395176). The CJC-1295 trials tested the long-acting version with DAC, a different drug. So this panel is a safety baseline. It doesn't prove the peptide is working.

Read this firstNo published human studies. A 2026 review of GH-axis peptides found that Mod GRF 1-29 "remains essentially uncharacterised in the peer-reviewed human literature" (PMID 42395176). Claims about how it works in people come from related compounds such as sermorelin and tesamorelin. FDA has not named Mod GRF 1-29 in its compounding safety review.

When to test

1. Baseline (before you start)

MarkerWhy test itStandard range
IGF-1
Insulin-like growth factor 1
Your reference point. With no human studies of Mod GRF 1-29, there is no expected change to compare against.Depends on age and sex. Labcorp adult examples: ages 21-25, men 109-353 and women 101-347; ages 41-45, men 84-270 and women 74-239; ages 56-60, men 68-247 and women 60-207 ng/mL
Source: Labcorp test 010363
Fasting glucose
Fasting plasma glucose
Growth hormone works against insulin (PMID 29025199), so you want to know your starting glucose before you push the GH axis. Fast for at least 8 hours before the draw.Normal under 100; prediabetes 100-125; diabetes 126 or higher mg/dL
Source: American Diabetes Association
HbA1c
Hemoglobin A1c
A one-off screen for existing blood-sugar problems. It reflects roughly the last 3 months, so it is too slow to show change within an 8-12 week cycle. Fasting glucose is the marker to repeat.Normal under 5.7%; prediabetes 5.7-6.4%; diabetes 6.5% or higher
Source: American Diabetes Association
CBC
Complete blood count
A standard safety baseline before any injectable peptide, so you have your own reference point if you feel unwell during the cycle.WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL
Source: Cleveland Clinic

2. Mid-cycle (week 4)

tracking only, no human data for Mod GRF 1-29

MarkerWhy test it
IGF-1
Insulin-like growth factor 1
Tracks against your baseline, same lab. Draw it before that day's dose. There is no human benchmark for how much it should move.
Fasting glucose
Fasting plasma glucose
The timely check on GH's effect on blood sugar. Same fasting conditions as baseline.

3. Post-cycle (2-4 weeks after your last dose)

MarkerWhy test it
IGF-1
Insulin-like growth factor 1
Compare with baseline and week 4.
Fasting glucose
Fasting plasma glucose
Confirms glucose is back where it started.

Ranges differ between labs. IGF-1 ranges also depend on age, sex and the assay the lab uses, so run every IGF-1 draw at the same lab and read it against the age band printed on your own report. Glucose and HbA1c cut-offs are the American Diabetes Association's diagnostic thresholds. CBC ranges come from Cleveland Clinic.

What to expect

  • IGF-1: no published human studies (baseline, week 4, post-cycle)

    Nobody has published IGF-1 results for Mod GRF 1-29 in people. Related GHRH-axis drugs do raise IGF-1: tesamorelin, a different, approved GHRH analog, raised it in a 6-month trial (PMID 20101189), and CJC-1295 with DAC raised it 1.5- to 3-fold (PMID 16352683). Neither is Mod GRF 1-29, which is short-acting where CJC-1295 with DAC lasts about a week.

    If it doesn't: IGF-1 can't vouch for your vial. A flat result doesn't prove the vial is fake, and a rise doesn't prove it's Mod GRF 1-29. Check the certificate of analysis for your batch.

  • Fasting glucose: may drift up; should stay in range (baseline, week 4, post-cycle)

    Growth hormone raises blood sugar by working against insulin (PMID 29025199). No human study has reported glucose on Mod GRF 1-29. Tesamorelin trials found no change in glucose parameters over 6 months (PMID 20101189) and no perturbation of glucose across five trials (PMID 41545261), but tesamorelin is a different drug.

    If it doesn't: A move from normal into the prediabetes range (100 or higher) is a reason to stop and talk to a clinician, whatever the source of the vial.

Your labs can't check your vial

Your labs can't check your vial, and with no human benchmark IGF-1 can't even hint. Danish customs seizures analysed by forensic chemists contained glycine-modified analogs of ipamorelin and modified GRF 1-29, not the compounds themselves (PMID 30136411), and a German survey of black-market products found peptide hormones among the doping agents seized (PMID 25168622). FDA has not named Mod GRF 1-29 in its compounding safety review. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.

Verify a lab certificate on ThirdPartyVerified →

What the research doesn't show

  • No published human studies of Mod GRF 1-29 exist (PMID 42395176). Everything about its effects in people is extrapolated from sermorelin, tesamorelin or CJC-1295 with DAC.
  • CJC-1295 trial results (PMID 16352683) are for the version with DAC, which binds albumin and lasts about a week. They do not apply to Mod GRF 1-29.
  • Tesamorelin data (PMID 20101189, PMID 41545261) comes from people with HIV-associated abdominal fat on 2 mg a day, a different drug in a different population.
  • Prolactin and cortisol are not on this panel. Reviews list rises in both as class effects of GH-axis peptides (PMID 42395176), but CJC-1295 with DAC did not raise them in humans (PMID 16352683). Unexplained breast tenderness or nipple discharge is a reason to see a clinician.
  • Banned in sport: the 2026 WADA Prohibited List bans GHRH analogues under S2, prohibited at all times. Mod GRF 1-29 is not named, but analogues are covered by the class.

Sources

  1. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026. PMID 42395176 (full text: PMC13322892)
  2. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
  3. Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr 2010. PMID 20101189
  4. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin: a meta-analysis of randomized controlled trials. Obes Res Clin Pract 2026. PMID 41545261
  5. Labcorp test 010363: Insulin-like growth factor 1 (IGF-1), age- and sex-specific reference ranges
  6. American Diabetes Association: Diagnosis (A1C and fasting plasma glucose thresholds)
  7. Cleveland Clinic: Complete blood count (normal values for adults)
  8. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 2017. PMID 29025199
  9. Gajda PM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal 2019. PMID 30136411
  10. Krug O, et al. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol 2014. PMID 25168622
  11. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Mod GRF 1-29 not named)
  12. German Sport University Cologne (WADA-accredited lab): S2 Peptide hormones, growth factors, related substances and mimetics (2026 Prohibited List)

Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.